

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Geographic atrophy | D057092 | — | — | 1 | 3 | — | — | — | 4 |
| Atrophy | D001284 | — | — | 1 | 3 | — | — | — | 4 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | Lampalizumab |
| INN | lampalizumab |
| Description | Lampalizumab (humanized mab) |
| Classification | Antibody |
| Drug class | ionotropic non-NMDA (N-methyl D-aspartate) glutamate receptors [AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) and/or KA (kainite antagonist) receptors]; monoclonal antibodies |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109408 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | UWU93Y99R3 (ChemIDplus, GSRS) |
